The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?
Open accessAbstract
Ischaemic stroke is a leading cause of death and long-lasting disability. Several neuroprotective drugs have been developed that have the potential to limit ischaemic brain damage and improve outcome for patients. While promising results with these drugs have been achieved in animal stroke models, all Phase III trials conducted so far indicate that these drugs have failed to live up to their promise. Despite the limits of animal models, which cannot mimic the clinical situation, the disappointing results of neuroprotective trials might largely be due to methodological problems. Future trials with neuroprotective drugs should be performed in stroke (care) units, after sufficient information regarding therapeutic time window, dosage, duration of therapy and safety has been gathered from pilot studies, and a better selection of target patients has been made. Much of this information can now be obtained by techniques that visualize the penumbra, such as combined diffusion-weighted and perfusion MRI. Consideration should also be given to clinical trials with well-designed combinations of treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Molecular characterization of mitochondrial apoptosis-inducing factor
Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., et al. (1999) · Nature · doi:10.1038/17135 · Cited by 4,060
Treatment of Acute Ischemic Stroke With Piracetam
De Deyn, P. P., De Reuck, J., Deberdt, W., Vlietinck, R., & Orgogozo, J.-M. (1997) · Stroke · doi:10.1161/01.str.28.12.2347 · Cited by 154
Cited by
NMDA receptor subunits: diversity, development and disease
Cull-Candy, S., Brickley, S., & Farrant, M. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00215-4 · Cited by 1,694
Durukan, A., & Tatlisumak, T. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.04.015 · Cited by 730
Shih, A. Y., Li, P., & Murphy, T. H. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4014-05.2005 · Cited by 413
γ‐Aminobutyric acidA neurotransmission and cerebral ischemia
Schwartz‐Bloom, R. D., & Sah, R. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00274.x · Cited by 323
Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels
Gribkoff, V. K., Starrett, J. E., Dworetzky, S. I., Hewawasam, P., Boissard, C. G., Cook, D. A., Frantz, S. W., Heman, K., Hibbard, J. R., Huston, K., et al. (2001) · Nature Medicine · doi:10.1038/86546 · Cited by 311
Metadata
- Authors
- De Keyser, J., Sulter, G., & Luiten, P. G.
- Venue
- Trends in Neurosciences
- Publisher
- Elsevier BV
- Published
- 1999-12
- Volume
- 22
- Issue
- 12
- Pages
- 535-540
- ISSN
- 0166-2236 (ISSN-L)
- OpenAlex
- W2093421851
- Cited by
- 374
- References
- 3
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? https://app.cochat.ai/papers/10.1016/s0166-2236(99)01463-0
- The paper
- De Keyser, J., Sulter, G., & Luiten, P. G. (1999). Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends in Neurosciences. https://doi.org/10.1016/s0166-2236(99)01463-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
